DE68918853D1 - Formulierung von menschlichen wachstumshormonen. - Google Patents

Formulierung von menschlichen wachstumshormonen.

Info

Publication number
DE68918853D1
DE68918853D1 DE68918853T DE68918853T DE68918853D1 DE 68918853 D1 DE68918853 D1 DE 68918853D1 DE 68918853 T DE68918853 T DE 68918853T DE 68918853 T DE68918853 T DE 68918853T DE 68918853 D1 DE68918853 D1 DE 68918853D1
Authority
DE
Germany
Prior art keywords
formulation
human growth
growth hormones
image
poloxamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68918853T
Other languages
English (en)
Other versions
DE68918853T2 (de
Inventor
Rodney Pearlman
James Oeswein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22667706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68918853(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE68918853D1 publication Critical patent/DE68918853D1/de
Publication of DE68918853T2 publication Critical patent/DE68918853T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Peptides Or Proteins (AREA)
DE68918853T 1988-04-15 1989-03-28 Formulierung von menschlichen wachstumshormonen. Expired - Lifetime DE68918853T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/182,262 US5096885A (en) 1988-04-15 1988-04-15 Human growth hormone formulation
PCT/US1989/001272 WO1989009614A1 (en) 1988-04-15 1989-03-28 Human growth hormone formulation

Publications (2)

Publication Number Publication Date
DE68918853D1 true DE68918853D1 (de) 1994-11-17
DE68918853T2 DE68918853T2 (de) 1995-04-13

Family

ID=22667706

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68918853T Expired - Lifetime DE68918853T2 (de) 1988-04-15 1989-03-28 Formulierung von menschlichen wachstumshormonen.

Country Status (9)

Country Link
US (1) US5096885A (de)
EP (2) EP0603159A3 (de)
JP (1) JP2747073B2 (de)
AT (1) ATE112685T1 (de)
AU (1) AU627174B2 (de)
CA (1) CA1329543C (de)
DE (1) DE68918853T2 (de)
NZ (1) NZ228747A (de)
WO (1) WO1989009614A1 (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
IL93986A0 (en) * 1989-04-04 1991-01-31 Lilly Co Eli Improvements in and relating to pharmaceutical formulations
DK372589D0 (da) * 1989-07-28 1989-07-28 Novo Nordisk As Protein
WO1991011195A1 (en) * 1990-02-02 1991-08-08 Novo Nordisk A/S A method of treating a mammal with a biologically active compound
AU7318691A (en) * 1990-02-02 1991-08-21 Novo Nordisk A/S A method of treating a mammal with a biologically active compound
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
AU1757092A (en) * 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
CA2337745C (en) * 1992-07-31 2005-04-12 Genentech, Inc. Human growth hormone aqueous formulation
CZ290342B6 (cs) * 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
CZ296649B6 (cs) * 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
JP3829991B2 (ja) * 1994-06-17 2006-10-04 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ Ｈｇｈ含有医薬組成物
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6790439B1 (en) 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
JP3869874B2 (ja) * 1995-11-15 2007-01-17 大日本住友製薬株式会社 急性肝不全治療剤
ES2208884T3 (es) 1996-01-25 2004-06-16 Schering Aktiengesellschaft Soluciones mejoradas de agentes de contraste para la administracion intravasal.
AU763521B2 (en) * 1996-01-25 2003-07-24 Schering Aktiengesellschaft Improved concentrated injection and infusion solutions for intravascular use
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
SE9704405D0 (sv) * 1997-11-28 1997-11-28 Pharmacia & Upjohn Ab New syringe
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
JP2003504346A (ja) * 1999-07-12 2003-02-04 グランデイス・バイオテツク・ゲー・エム・ベー・ハー 成長ホルモン製剤
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
EP1232174B1 (de) 1999-11-18 2013-05-01 Ischemix, Inc Zubereitungen und verfahren zur bekämpfung der effekte reaktiver sauerstoff-teilchen und freier radikaler
MXPA02008261A (es) 2000-02-24 2002-11-29 Monsanto Technology Llc Formulaciones inyectables no acuosas para liberacion prolongada de somatotorpina.
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
IL152360A0 (en) 2000-04-19 2003-05-29 Genentech Inc Sustained release formulations
KR20030023878A (ko) 2000-06-26 2003-03-20 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
EP2116265B1 (de) * 2000-10-12 2020-12-23 Genentech, Inc. Niederviskose konzentrierte Proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US7824700B2 (en) * 2001-02-23 2010-11-02 Genentech, Inc. Erodible polymers for injection
US7271150B2 (en) * 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
EP1401862A4 (de) * 2001-05-17 2004-12-15 Ceremedix Inc Peptidverbindungen, die reaktiven sauerstoffspezies und freien radikalen entgegenwirken
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1397155B1 (de) * 2001-06-21 2015-09-30 Genentech, Inc. Formulierung mit verzögerter freisetzung
EP1997829A1 (de) * 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin Fusionsproteine
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20070065469A1 (en) * 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
CN100475267C (zh) * 2002-07-09 2009-04-08 桑多斯股份公司 含甘氨酸的高浓度人生长激素液体制剂
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2004091658A1 (en) * 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
CA2540172A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
JP5522939B2 (ja) * 2005-11-02 2014-06-18 トランスファーマ メディカル リミテッド ヒト成長ホルモンパッチ製剤
MX2009012609A (es) * 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
TW201039854A (en) * 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
RS56409B1 (sr) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
EA201391605A1 (ru) * 2011-04-29 2014-02-28 Онколитикс Байотек Инк. Способы очистки вирусов с использованием гельпроникающей хроматографии
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP6464145B2 (ja) * 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
CN112566652A (zh) * 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
CN111329996B (zh) * 2020-03-03 2023-11-03 上海联合赛尔生物工程有限公司 重组人生长激素的组合物和其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0158487B1 (de) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stabile Interleukin-2-Zusammensetzung
EP0193917A3 (de) * 1985-03-06 1987-09-23 American Cyanamid Company Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
PT83095B (en) * 1985-07-30 1987-12-23 Int Minerals & Chem Corp Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers
ES2044941T5 (es) * 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.

Also Published As

Publication number Publication date
EP0409870A1 (de) 1991-01-30
WO1989009614A1 (en) 1989-10-19
JP2747073B2 (ja) 1998-05-06
DE68918853T2 (de) 1995-04-13
CA1329543C (en) 1994-05-17
EP0409870B1 (de) 1994-10-12
EP0603159A3 (de) 1995-12-13
EP0603159A2 (de) 1994-06-22
AU3368789A (en) 1989-11-03
AU627174B2 (en) 1992-08-20
NZ228747A (en) 1991-09-25
US5096885A (en) 1992-03-17
JPH03503764A (ja) 1991-08-22
ATE112685T1 (de) 1994-10-15

Similar Documents

Publication Publication Date Title
DE68918853D1 (de) Formulierung von menschlichen wachstumshormonen.
NO179479C (no) Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
FI88459B (fi) Foerfarande foer framstaellning av en foer intranasal applikation laemplig steroidkomposition
DE3779933D1 (de) Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung.
DZ1067A1 (fr) Nouvelles préparations pharmaceutiques à emission prolongée.
OA09850A (fr) Conjugués d'interféron et composés les contenant.
DK0667166T3 (da) Emulsionspræparat med 1alpha, 24-(OH)2-vitamin D3
SE9202066L (sv) Prokaterol-haltigt preparat foer paafoering paa huden
ATE127683T1 (de) Stabile emulgierte tretinoin-cremeformulierungen.
DE69325236D1 (de) Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure
DE69229857D1 (de) Zusammensetzung zur verwendung in der transdermalen verabreichung
DK0639202T3 (da) Stabil polypeptidsammensætning
ZA91115B (en) Topical compositions
IT7850274A0 (it) Applicazione terapeutica di trimethoprim e derivati dell'acido n-etil-piridone-3 carbossilico
IT8619288A0 (it) Formulazioni farmaceutiche iniettabili di principi attivi adattivita' anestetica generale.
DK661888A (da) Biologisk aktive molekyler

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings